NASDAQ:OBLN Obalon Therapeutics (OBLN) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free OBLN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.17▼$0.1850-Day Range$2.36▼$7.6452-Week Range$0.66▼$10.77Volume72,857 shsAverage Volume7.68 million shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsInsider TradesSocial MediaStock AnalysisCompetitorsInsider TradesSocial Media Get Obalon Therapeutics alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Obalon Therapeutics Stock (NASDAQ:OBLN)Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.Read More Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. OBLN Stock News HeadlinesFebruary 25, 2024 | thestreet.comObalon Therapeutics, Inc.February 6, 2024 | wsj.comSpero Therapeutics Inc.May 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.March 28, 2023 | marketwatch.comIntragastric Balloon Market Growth and Forecast till 2031August 17, 2022 | marketwatch.comIntragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 PagesJanuary 5, 2022 | investing.comRenovare Environmental Inc (RENO)August 10, 2021 | benzinga.comUnderstanding Atara Biotherapeutics's Unusual Options ActivitySee More Headlines Receive OBLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Obalon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2021Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:OBLN CUSIPN/A CIK1427570 Webwww.obalon.com Phone(844) 362-2566FaxN/AEmployees2Year Founded2008Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,330,000.00 Net Margins-776.76% Pretax MarginN/A Return on Equity-161.38% Return on Assets-83.58% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.86 Sales & Book Value Annual Sales$1.59 million Price / Sales1.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book0.28Miscellaneous Outstanding Shares10,022,000Free FloatN/AMarket Cap$1.70 million OptionableNot Optionable Beta-1.23 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Andrew P. Rasdal (Age 63)CEO, Pres & Director Comp: $160.31kMs. Nooshin Hussainy (Age 63)CFO & Sec. Comp: $140.29kDr. Kelly Huang Ph.D. (Age 52)Consultant Key CompetitorsProSomnusNASDAQ:OSAPProSomnusNASDAQ:OSALianluo SmartNASDAQ:LLITBluejay DiagnosticsNASDAQ:BJDXReShape LifesciencesNASDAQ:RSLSView All Competitors OBLN Stock Analysis - Frequently Asked Questions How were Obalon Therapeutics' earnings last quarter? Obalon Therapeutics, Inc. (NASDAQ:OBLN) posted its quarterly earnings data on Thursday, March, 11th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.11. The business earned $0.06 million during the quarter. Obalon Therapeutics had a negative net margin of 776.76% and a negative trailing twelve-month return on equity of 161.38%. When did Obalon Therapeutics' stock split? Obalon Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Obalon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Co-Diagnostics (CODX), NIO (NIO), Novavax (NVAX) and Onconova Therapeutics (ONTX). When did Obalon Therapeutics IPO? Obalon Therapeutics (OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager. This page (NASDAQ:OBLN) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe asset beating inflation by 4xColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
